3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
12
Unknown
2
Terminated
2
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Neuroblastoma
3
Lymphoma
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Unspecified Childhood Solid Tumor, Protocol Specific
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Sertoli-Leydig Cell Tumor
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian gynandroblastoma
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Leukemia
1
Immunoblastic Lymphadenopathy
1
Granulosa cell tumor of the ovary
1
Glioma
1
Fallopian Tube Neoplasms
1
Enteropathy-Associated T-Cell Lymphoma
1
Carcinoma, Ovarian Epithelial
1
Interventions
Cyclophosphamide
27
Rituximab
20
Etoposide
14
Cytarabine
13
Melphalan
11
Vincristine
10
fludarabine
9
Prednisone
9
Doxorubicin
9
Busulfan
8
Peripheral Blood Stem Cell Transplantation
7
Radiotherapy
6
Filgrastim
6
Cyclosporine
6
Bendamustine Hydrochloride
6
fludarabine phosphate
5
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
5
Mycophenolic Acid
5
Cisplatin
5
tositumomab I-131
4
ibritumomab tiuxetan
4
Ifosfamide
4
Dexamethasone
4
Carmustine
4
relmacabtagene autoleucel
3
Thiotepa
3
Indium
3
Immunotherapy, Adoptive
3
Gemcitabine
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
Lymphoma, Non-Hodgkin
×
etoposide phosphate
×
Clear all
NCT00324467
2021-07-22
LYTPET
British Columbia Cancer Agency
Phase 2
Unknown
150 enrolled
NCT00946374
2009-07-27
HD-MCL2003
Heidelberg University
Phase 2
Unknown
20 enrolled